ERBB2 and neoplasm: The most common subtype, assessed on primary tumor, was hormone receptor (HR) positive Her2 negative (16; 40%), followed by Her2 positive (14; 35%) and triple-negative breast cancer (TNBC) (10 patients, 25%, Fig. 1).